Want to see FR:ALIMP full AI Analyst Report?
Top Page
Implanet SA
(ALIMP)
Select Model
Select Model
Rating:45Neutral
Price Target:
€0.16
▼(-38.85% Downside)
Action:Reiterated
Date:10/15/26
The score is held back primarily by weak financial quality: persistent losses, ongoing negative operating/free cash flow, and a highly leveraged balance sheet with minimal equity cushion, despite improving revenue growth and gross margin. Technical signals are mostly neutral-to-soft with the price below key longer-term moving averages. Valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
Revenue Growth
The strong rebound in revenue indicates improving commercial traction for Implanet’s orthopedic and spine products. Sustained top-line expansion can broaden the installed customer base, support operating leverage, and provide a foundation for future earnings improvement if growth continues.
Negative Factors
Persistent Losses
Persistent operating and net losses show that revenue growth and better gross margins have not yet translated into a sustainable earnings model. Until profitability improves, Implanet may have less capacity to reinvest, absorb setbacks, or build equity internally.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The strong rebound in revenue indicates improving commercial traction for Implanet’s orthopedic and spine products. Sustained top-line expansion can broaden the installed customer base, support operating leverage, and provide a foundation for future earnings improvement if growth continues.
Read all positive factors
Implanet SA (ALIMP) vs. iShares MSCI France ETF (EWQ)
Market Cap
€21.43M
Dividend YieldN/A
Average Volume (3M)72.15K
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue Growth24.35%
EPS Growth15.00%
CountryFR
Employees49
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.03
Shares Outstanding143,818,970
10 Day Avg. Volume121,935
30 Day Avg. Volume72,153
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)70.59
Price to Sales (P/S)2.29
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Implanet SA Business Overview & Revenue Model
Company Description
Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. It...
How the Company Makes Money
Implanet generates revenue primarily from selling orthopedic and spine implant products and the associated surgical instruments/ancillaries required to perform procedures using its systems. Revenue is typically recognized through product sales to ...
Implanet SA Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.80M | 12.47M | 9.41M | 7.45M | 8.03M | 6.14M |
| Gross Profit | 8.08M | 5.93M | 4.10M | 3.13M | 3.91M | 2.74M |
| EBITDA | -3.78M | -2.91M | -3.82M | -5.08M | -1.84M | -2.70M |
| Net Income | -4.42M | -4.38M | -4.37M | -6.68M | -3.54M | -4.61M |
Balance Sheet | ||||||
| Total Assets | 17.74M | 18.45M | 14.89M | 10.64M | 14.47M | 16.70M |
| Cash, Cash Equivalents and Short-Term Investments | 1.01M | 3.01M | 1.60M | 248.00K | 531.00K | 1.87M |
| Total Debt | 5.46M | 5.92M | 6.50M | 6.15M | 6.80M | 9.61M |
| Total Liabilities | 19.46M | 18.04M | 14.16M | 10.81M | 10.93M | 13.90M |
| Stockholders Equity | -1.72M | 404.00K | 727.00K | -174.00K | 3.54M | 2.80M |
Cash Flow | ||||||
| Free Cash Flow | -2.29M | -2.15M | -2.81M | -2.17M | -3.04M | -3.91M |
| Operating Cash Flow | -733.00K | -589.00K | -2.32M | -1.45M | -2.47M | -3.52M |
| Investing Cash Flow | -1.62M | -1.56M | -844.00K | -768.00K | -570.00K | 1.57M |
| Financing Cash Flow | 2.96M | 3.64M | 4.37M | 1.95M | 1.60M | 2.73M |
Implanet SA Technical Analysis
Negative
0.26
Price Trends
0.17
Negative
0.17
Negative
0.19
Negative
Market Momentum
>-0.01
Positive
42.13
Neutral
54.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALIMP, the sentiment is Negative. The current price of 0.26 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.17, and above the 200-day MA of 0.19, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.13 is Neutral, neither overbought nor oversold. The STOCH value of 54.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALIMP.
Implanet SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | €344.74M | -8.52 | -120.57% | ― | -100.00% | -72.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | €21.43M | -5.19 | 671.47% | ― | 24.35% | 15.00% | |
45 Neutral | €18.88M | 1.53 | -157.72% | ― | 3.38% | ― | |
43 Neutral | €50.83M | -6.66 | 453.10% | ― | -16.98% | 20.31% | |
41 Neutral | €214.18M | -3.80 | 90.10% | ― | 1.79% | 15.89% |
* Healthcare Sector Average
FR:ALIMP
Implanet SA
0.15
-0.13
-46.79%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.10
0.00
0.00%
FR:ALTHE
Theraclion SA
0.69
0.10
16.78%
FR:ALDMS
Diagnostic Medical Systems
0.94
-0.39
-29.17%
FR:ALMDT
Median Technologies
4.37
1.47
50.69%
FR:CVX
Affluent Medical SA
5.54
4.10
284.72%
Implanet SA Corporate Events
Implanet extends growth streak on spine implants and U.S. surge
Oct 13, 2026
Implanet reported its ninth consecutive quarter of growth, with third-quarter 2026 revenue up 18% to €3.44 million and nine‑month revenue rising 21% to €10.57 million, driven by strong demand for spine implants and SMTP medical e...
Implanet lifts H1 revenue 23% as Jazz Spinal System drives margin gains
Sep 15, 2026
Implanet reported first-half 2026 revenue of €7.1 million, up 23% year-on-year, with growth driven by its spine implants business and the strong performance of the new Jazz Spinal System hybrid posterior fixation solution. Sales of the SMTP ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.